• Explore /
  • Poster
  • / Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA <i>EGFR</i> positive (IHC/FISH) non-small cell lung cancer (NSCLC).

Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Mary E.R. O'Brien

Royal Marsden Hospital, London, United Kingdom

Mary E.R. O'Brien , Karen Kelly , Nasser K. Altorki , Wilfried Ernst Erich Eberhardt , David R. Spigel , Lucio Crino , Chun-Ming Tsai , Joo-Hang Kim , Eun Kyung Cho , Philip C. Hoffman , Shaf Keshavjee , Sergey Orlov , Piotr Serwatowski , Joe Wang , Margaret A. Foley , Julie D. Horan , Frances A. Shepherd

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT00373425

Citation

J Clin Oncol 33, 2015 (suppl; abstr 7540)

DOI

10.1200/jco.2015.33.15_suppl.7540

Abstract #

7540

Poster Bd #

287

Abstract Disclosures

Similar Posters

First Author: Li Zhang

First Author: Hongyun Zhao

First Author: Michael J. Boyer

First Author: Hirohito Tada